DSGN Design Therapeutics, Inc.: institutional ownership and insider trading
139 funds reported holding $665M of Design Therapeutics, Inc. in their latest 13F filings; in Q2 2026 funds net bought $99.4M, with 27 new positions and 16 funds selling out; over the last 12 months insiders bought $0 and sold $0 on the open market.
Famous investors holding DSGN
- Renaissance Technologies (Renaissance Technologies): $5.61M, 0.0% of the portfolio
- D. E. Shaw (D. E. Shaw & Co.): $2.83M, 0.0% of the portfolio
- Izzy Englander (Millennium Management): $2.14M, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $1.39M, 0.0% of the portfolio
- Two Sigma (Two Sigma Investments): $476K, 0.0% of the portfolio
Largest institutional holders of DSGN
- SR ONE CAPITAL MANAGEMENT, LP — $94.4M
- Logos Global Management LP — $43.4M
- BAKER BROS. ADVISORS LP — $38.8M
- DRIEHAUS CAPITAL MANAGEMENT LLC — $38.5M
- BlackRock, Inc. (BLK) — $38.5M
- Caption Management, LLC — $37.9M
- Point72 Asset Management, L.P. — $34.2M
- Trails Edge Capital Partners, LP — $29.0M
- Frazier Life Sciences Management, L.P. — $26.2M
- Vivo Capital, LLC — $23.3M
Recent DSGN insider trades
- Aug 13, 2025: William Arsani sold 562,627 shares ($2.95M)
- Dec 18, 2024: Prasad Deepa sold 3,806 shares ($23.9K)
5%+ owners
- Sirenia Capital Management LP: 9.5% (Schedule 13G, filed Aug 14, 2026)